ADRB2 and breast cancer: It has been demonstrated that approximately 30-40% of CD4+ and CD8+ BC-infiltrating T cells express β2-AR and that blockade of β-AR signaling results in downregulation of PD-1 and increased production of IFN-γ in these cells 35.